LCTX director granted 125,000 stock options

Lineage Cell Therapeutics director Anula Jayasuriya received a stock option grant covering 125,000 common shares.

Rhea-AI Filing Summary

Lineage Cell Therapeutics director Anula Jayasuriya received a stock option grant covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.

The option will vest and become exercisable on the earlier of July 1, 2027 and the company’s next annual meeting of shareholders, subject to Jayasuriya’s continuous service with the company. Following this grant, the filing shows 125,000 derivative securities held directly.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Jayasuriya Anula

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

Key Figures

Option grant size: 125,000 options Exercise price: $1.30 per share Underlying shares: 125,000 shares +3 more

6 metrics

Option grant size 125,000 options Stock Option (Right to Buy) granted to director

Exercise price $1.30 per share Conversion or exercise price of stock options

Underlying shares 125,000 shares Common shares underlying the stock options

Expiration date July 1, 2036 Option expiration for the grant

Vesting date Earlier of July 1, 2027 or next annual meeting Vesting condition subject to continuous service

Post-grant holdings 125,000 derivative securities Total options held directly after transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of shareholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of shareholders financial

"the issuer's next annual meeting of shareholders, subject in any case"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lineage Cell Therapeutics (LCTX) director Anula Jayasuriya report on this Form 4?

Director Anula Jayasuriya reported receiving a grant of stock options for 125,000 common shares. These are compensation-related derivative awards, not open-market share purchases, and give her the right to buy shares at a fixed exercise price in the future.

How many Lineage Cell Therapeutics (LCTX) options were granted and at what exercise price?

The filing shows a grant of stock options covering 125,000 common shares at an exercise price of $1.30 per share. This price is the fixed cost Jayasuriya would pay to convert the options into common shares if and when they vest.

When do Anula Jayasuriya’s new LCTX stock options vest and become exercisable?

The options vest and become exercisable on the earlier of July 1, 2027 and Lineage Cell Therapeutics’ next annual meeting of shareholders. Vesting is conditioned on Jayasuriya’s continuous service with the company through that applicable vesting date.

What is the expiration date of the LCTX stock options granted to Anula Jayasuriya?

The granted stock options expire on July 1, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Lineage Cell Therapeutics common shares at the $1.30 exercise price.

Are the LCTX transactions reported by Anula Jayasuriya open-market trades?

No, the Form 4 reports a compensation-related stock option grant coded as “A” for grant, award, or other acquisition. There were no open-market buy or sell trades; this filing only reflects receipt of derivative awards from the company.

How many derivative securities does Anula Jayasuriya hold after this LCTX option grant?

Following the reported transaction, the Form 4 shows Jayasuriya directly holding 125,000 derivative securities. These represent stock options tied to 125,000 underlying Lineage Cell Therapeutics common shares, subject to the vesting and expiration terms disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jayasuriya Anula

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	Common Shares	125,000	$0.00	125,000	D

Explanation of Responses:

1. Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.

	/s/ Alexandra Hernandez, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)